Now a two-time los­er, As­traZeneca’s hopes for selume­tinib dwin­dle af­ter an­oth­er PhI­II flop

As­traZeneca’s one-time block­buster hope­ful selume­tinib is now a two-time los­er in late-stage de­vel­op­ment. The phar­ma gi­ant was forced to con­cede Tues­day morn­ing that the drug flopped in KRAS-pos­i­tive non-small cell lung can­cer. The drug whiffed on pro­gres­sion-free sur­vival and failed to score on over­all sur­vival as well.

As­traZeneca had to walk away from the first Phase III for selume­tinib last year af­ter the drug — in-li­censed from Ar­ray — failed for an eye can­cer called uveal melanoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER